Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00090051 · FLOW

Participant flow

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients · Source last updated 2017-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV on Days 1, 2, 3 for 6 cycles.
    id
    FG000
    title
    Fludarabine+Cyclophosphamide (FC)
  2. description
    Rituximab and FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: rituximab 375 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 2, 3, 4; cyclophosphamide 250 mg/m² IV on Days 2, 3, 4. Cycles 2-6: rituximab 500 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 1, 2, 3; cyclophosphamide 250 mg/m² IV on Days 1, 2, 3.
    id
    FG001
    title
    Fludarabine+Cyclophosphamide+Rituximab (FCR)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        276
      2. group Id
        FG001
        num Subjects
        276
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        272
      2. group Id
        FG001
        num Subjects
        274
      type
      Safety Population; Received Study Drug
    3. achievements
      1. comment
        Completed 6 Cycles of Treatment
        group Id
        FG000
        num Subjects
        167
      2. comment
        Completed 6 Cycles of Treatment
        group Id
        FG001
        num Subjects
        181
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        109
      2. group Id
        FG001
        num Subjects
        95
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV on Days 1, 2, 3 for 6 cycles.
    id
    FG000
    title
    Fludarabine+Cyclophosphamide (FC)
  2. description
    Rituximab and FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: rituximab 375 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 2, 3, 4; cyclophosphamide 250 mg/m² IV on Days 2, 3, 4. Cycles 2-6: rituximab 500 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 1, 2, 3; cyclophosphamide 250 mg/m² IV on Days 1, 2, 3.
    id
    FG001
    title
    Fludarabine+Cyclophosphamide+Rituximab (FCR)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        276
      2. group Id
        FG001
        num Subjects
        276
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        272
      2. group Id
        FG001
        num Subjects
        274
      type
      Safety Population; Received Study Drug
    3. achievements
      1. comment
        Completed 6 Cycles of Treatment
        group Id
        FG000
        num Subjects
        167
      2. comment
        Completed 6 Cycles of Treatment
        group Id
        FG001
        num Subjects
        181
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        109
      2. group Id
        FG001
        num Subjects
        95
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice